Amid sequence of failures, Jakafi offers hope for Incyte

21 June 2018

At its 2018 Investor and Analyst Event, Incyte's (Nasdaq: INCY) recent suffering continued with the announcement that it planned to scrap one of its clinical trials.

CITADEL-202 trialled Incyte's candidate INCB50465 in patients with diffuse large-B cell lymphoma, but it was announced on Thursday that this trial would now be suspended.

The news follows the abrupt and unexpected failure of Incyte's combination epacadostat-Keytruda (pembrolizumab) therapy, devised in collaboration with Merck & Co (NYSE: MRK), in Phase III trials just two months ago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK